BioSight

Company Overview

Snapshot

Founded in November 1999 by Stela Gengrinovitch, PhD and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised a total of $62.5M across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals.

Business overview

BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (aspacytarabine), is a proprietary anti-metabolite designed to deliver high-dose therapy with reduced systemic toxicity. The company is currently investigating BST-236 as a single agent in a Phase 2b trial for first-line treatment of acute myeloid leukemia (AML), building on promising efficacy and tolerability demonstrated in earlier trials for AML patients unsuitable for standard therapy. BioSight operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and biotechnology industries with its oncology and hematology drug discovery and development efforts.

Strategic signal

In November 2022, BioSight initiated a Phase 1/2 clinical trial for Aspacytarabine in combination with Venetoclax for first-line AML induction therapy, followed by Aspacytarabine consolidation. This development signals the company's commitment to advancing its lead product and exploring combination therapies to enhance treatment outcomes for acute myeloid leukemia, indicating a strategic focus on expanding the clinical utility and market potential of its therapeutic pipeline prior to its acquisition.

Company Intelligence Q&A

What was BioSight's most recent corporate milestone?

In October 2023, BioSight was acquired by Ayala Pharmaceuticals, marking a significant exit for the company.

When did BioSight launch a new clinical trial for Aspacytarabine?

In November 2022, BioSight launched a Phase 1/2 clinical trial for Aspacytarabine in combination with Venetoclax for first-line AML induction therapy, followed by Aspacytarabine consolidation.

When did BioSight receive FDA Fast Track Designation for BST-236?

In August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of Acute Myeloid Leukemia.

Which investors participated in BioSight's Series C funding round in March 2020?

In March 2020, BioSight secured Series C funding with participation from Israel Biotech Fund.

When did BioSight receive Orphan Drug Designation from the FDA for BST-236?

In June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the treatment of Acute Myeloid Leukemia.